Risk of recurrence of ductal carcinoma in situ by oncotype Dx technology: Some concerns

Author： Lagios Michael D.   Silverstein Melvin J.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|7|1085-1085

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.7, 2014-04, pp. : 1085-1085

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Keeping abreast of Oncotype DX testing

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 651, 2012-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

OncotypeDX-guided treatment of breast cancer cost effective

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 529, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

NICE recommends Oncotype DX to guide breast cancer therapy . . .

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 672, 2013-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Oncotype DX testing a winner for guiding breast cancer therapy

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 645, 2012-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Breast MR-Imaging of Ductal Carcinoma In Situ: A Systematic Review

By Schmitz A. C.   Smits M. L. J.   Veldhuis W.   van der Wall E.   van Hillegersberg R.   Borel-Rinkes I. H. M.   Mali W. P. Th. M.   van den Bosch M. A. A. J.  

Imaging Decisions MRI, Vol. 13, Iss. 3-4, 2009-0 ,pp. : 112-121

Blackwell Publishing

Access to resources Recommend Favorite